FOXO4-DRI

FOXO4-D-Retro-Inverso

Rank#999
Anti AgingNot ApprovedAnimalResearchSubQ

Popular for:Senolytic, eliminates senescent cells, anti-aging

16

Total Studies

7

Human Studies

Animal

Evidence Level

Not Approved

FDA Status

Overview

FOXO4-DRI is a D-retro-inverso peptide designed to selectively eliminate senescent cells (often called 'zombie cells') by disrupting the FOXO4-p53 interaction that keeps damaged cells alive. It was developed based on a landmark 2017 study published in Cell by Peter de Keizer's lab at Erasmus University Medical Center.

Senescent cells accumulate with age and secrete inflammatory factors (the SASP — senescence-associated secretory phenotype) that damage surrounding healthy tissue. FOXO4-DRI represents one of the most targeted senolytic approaches, designed to trigger apoptosis specifically in senescent cells while leaving healthy cells unaffected.

Mechanism of Action

In senescent cells, FOXO4 binds to p53, sequestering it and preventing p53 from triggering apoptosis. FOXO4-DRI is a modified peptide that competes with endogenous FOXO4 for p53 binding, displacing the FOXO4-p53 interaction. This frees p53 to activate apoptotic pathways, selectively killing the senescent cell. Healthy cells are unaffected because they do not depend on the FOXO4-p53 interaction for survival.

Key Research Benefits

Selectively targets and eliminates senescent cells
Based on peer-reviewed research (Cell, 2017)
Restored fur density and kidney function in aged mice
Targeted mechanism spares healthy cells
Represents cutting-edge senolytic research

Clinical Evidence Summary

Research Pipeline

Preclinical
Animal
Phase I
Phase II
Phase III
Approved

16

Total Studies

7

Human Studies

Not FDA-approved. Pre-clinical research compound. Based on de Keizer et al., Cell 2017. No human clinical trials completed. One of the most expensive research peptides due to synthesis complexity.

Key Studies / PubMed References

FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway.

In Vitro

Hu Z, Li F, Hu C, et al. · Frontiers in bioengineering and biotechnology · 2025

PMID: 41625068

The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.

In Vitro

Bourgeois B, Spreitzer E, Platero-Rochart D, et al. · Nature communications · 2025

PMID: 40593617

FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation.

In Vitro

Kong YX, Li ZS, Liu YB, et al. · Communications biology · 2025

PMID: 39994346

FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells.

In Vitro

Li Y, Zhang C, Cheng H, et al. · Experimental gerontology · 2024

PMID: 39025385

Cellular Senescence Contributes to the Progression of Hyperoxic Bronchopulmonary Dysplasia.

Animal Study

Jing X, Jia S, Teng M, et al. · American journal of respiratory cell and molecular biology · 2024

PMID: 37874230

Side Effects & Safety

Limited human safety data
Potential for off-target effects not fully characterized
Research primarily in animal models
High cost due to complex D-retro-inverso synthesis

Known Interactions

No curated interaction entry is live for FOXO4-DRI yet.

Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.

Frequently Asked Questions

Research Disclaimer

This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. FOXO4-DRI is not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before making any health-related decisions. The studies referenced are linked to their original PubMed sources for verification.